<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>xenograft models &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/xenograft-models/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Fri, 09 Oct 2026 05:30:16 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>xenograft models &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>β-Catenin Inhibitors Show Potent Activity Against Double-Mutant Endometrial Cancer in Preclinical Study</title>
		<link>https://bioengineer.org/%ce%b2-catenin-inhibitors-show-potent-activity-against-double-mutant-endometrial-cancer-in-preclinical-study/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Fri, 09 Oct 2026 05:30:16 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[CTNNB1]]></category>
		<category><![CDATA[endometrial cancer]]></category>
		<category><![CDATA[ICG-001]]></category>
		<category><![CDATA[PI3K/AKT/mTOR]]></category>
		<category><![CDATA[PIK3CA]]></category>
		<category><![CDATA[precision oncology]]></category>
		<category><![CDATA[proteostasis]]></category>
		<category><![CDATA[proteotoxic stress]]></category>
		<category><![CDATA[targeted therapy]]></category>
		<category><![CDATA[Wnt Signaling]]></category>
		<category><![CDATA[xenograft models]]></category>
		<category><![CDATA[β-catenin]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=409522</guid>

					<description><![CDATA[A new preclinical study shows that the β-catenin/CBP inhibitor ICG-001 selectively kills endometrial cancer cells carrying both PIK3CA and CTNNB1 mutations by triggering catastrophic proteostasis collapse, with robust antitumor effects confirmed in xenograft models.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">409522</post-id>	</item>
	</channel>
</rss>
